Physicochemical Properties
| Molecular Formula | C30H31CL2N7O4 |
| Molecular Weight | 624.52 |
| Exact Mass | 623.181 |
| CAS # | 1386980-55-7 |
| Related CAS # | DYRKs-IN-1;1387090-01-8 |
| PubChem CID | 144416250 |
| Appearance | Yellow to brown solid powder |
| Hydrogen Bond Donor Count | 5 |
| Hydrogen Bond Acceptor Count | 8 |
| Rotatable Bond Count | 8 |
| Heavy Atom Count | 43 |
| Complexity | 1030 |
| Defined Atom Stereocenter Count | 0 |
| SMILES | O=C1C(=CC2=CN=C(N3CC4CCC(O4)C3)NC2=N1)C(=O)NC1C(=CC=C(C(=O)NC(C2C=CC=CC=2)CCN)C=1)Cl.Cl |
| InChi Key | XLHHYTUBPOMTDK-UHFFFAOYSA-N |
| InChi Code | InChI=1S/C30H30ClN7O4.ClH/c31-23-9-6-18(27(39)34-24(10-11-32)17-4-2-1-3-5-17)13-25(23)35-28(40)22-12-19-14-33-30(37-26(19)36-29(22)41)38-15-20-7-8-21(16-38)42-20;/h1-6,9,12-14,20-21,24H,7-8,10-11,15-16,32H2,(H,34,39)(H,35,40)(H,33,36,37,41);1H |
| Chemical Name | N-[5-[(3-amino-1-phenylpropyl)carbamoyl]-2-chlorophenyl]-2-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-7-oxo-8H-pyrido[2,3-d]pyrimidine-6-carboxamide;hydrochloride |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| Targets | DYRK1A 5 nM (IC50) DYRK1B 8 nM (IC50) |
| ln Vitro | DYRKs-IN-1 hydrochloride (compound 30) has an EC50 of 27 nM and improves the cellular potency against the human colon carcinoma cell line SW 620[1]. A strong inhibitor of DYRKs is DYRKs-IN-1 hydrochloride (Example 183)[2]. |
| References |
[1]. Pyrido[2,3-d]pyrimidines: discovery and preliminary SAR of a novel series of DYRK1B and DYRK1A inhibitors. Bioorg Med Chem Lett. 2013 Dec 15;23(24):6610-5. [2]. Pyrido pyrimidines. US20120184542A1. |
Solubility Data
| Solubility (In Vitro) |
DMSO: 20.83 mg/mL (33.35 mM) H2O: < 0.1 mg/mL |
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (3.33 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (3.33 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 2.08 mg/mL (3.33 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.6012 mL | 8.0061 mL | 16.0123 mL | |
| 5 mM | 0.3202 mL | 1.6012 mL | 3.2025 mL | |
| 10 mM | 0.1601 mL | 0.8006 mL | 1.6012 mL |